IMUNON Announces Its Phase 3 OVATION 3 Trial Of IMNN-001 In Patients With Ovarian Cancer Has Observed Rapid Site Activation And Above-Forecast Enrollment Rate
The trial advanced from protocol submission to site activation in approximately 6 months and from protocol approval to first patient randomized in approximately 2 months, a third of the time of the external industry
IMUNON's cancer medicine trial is moving faster than normal—doctors signed up and patients joined the study much quicker than usual. This shows the company might be running things smoothly, but we'll need to see if the medicine actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.